The special relationship between the UK and US has been going strong for decades’ now with both countries cultures and industries working together to promote prosperity from both sides “across the pond”.
Whilst there is a lot to be proud of, there are also several areas where the two countries could work together better. The pharma industry is one such area.
The US, the UK and in fact the entirety of Europe already collaborate strongly with one another when it comes to biotech, however new research from Alacrita has revealed that US pharma execs often consider European regulations far too late in processes such as drug development.
Questions have also been raised about the upcoming Brexit decision and how this will affect collaboration, and the strategic positioning of US headquarters in Europe.
An infographic has been created to highlight the current state of this special pharma relationship. It highlights how US pharma execs currently view the European market and how they take the continent into consideration during production.
You can take a look at the infographic below:
Provided by Alacrita